title: [The relationship of serum HBsAg, HBeAg concentration and HBV-DNA load in chronic hepatitis B during IFN treatment].
abstract: OBJECTIVE
  To investigate the relation of serum HBsAg, HBeAg contents and HBV-DNA load changes in HBeAg-positive chronic hepatitis B during IFN-alpha treatment.
  
  
  METHODS
  After enrolled, the patients were treated with 3MU-5MU IFN subcutaneous injection every two days, and their serum was collected before treatment and every 3 months during the treatment course. The serum HBV-DNA load was determined by real-time fluorescence quantitative PCR method kit (lower detection limit 500 copies/ml, Piji company, Shenzhen city, China,) according to production instruction, and HBeAg and HBsAg contents were detected by ARCHITECH I 2000.chemiluminescent kit. The relation of serum HBV-DNA, HBeAg and HBsAg content was analyzed by SPSS statistic software.
  
  
  RESULTS
  There were 228 patients enrolled into this group, male 162 cases, female 66 cases, aged 14-60 years, average 30.94 years old. After IFN treatment the HBV-DNA, HBeAg and HBsAg levels were all gradually decreased. But there was no relation of HBsAg content to HBV DNA and HBeAg content before and during treatment course(P > 0.05). However the serum HBeAg content was related to HBV-DNA content significantly (P < 0.05) and their changes was correspondence.
  
  
  CONCLUSIONS
  Before and during treatment of interferon, HBeAg and HBV-DNA content changes are closely related, while there is no significant correlation between HBsAg and HBeAg and HBV-DNA content. During interferon therapy, HBsAg, HBeAg, HBV-DNA contents should be detected together.
authors.affiliation: The center of liver diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
authors.forename: Ming-hui
authors.initials: MH
authors.lastname: Li
authors.forename: Yao
authors.initials: Y
authors.lastname: Xie
authors.forename: Guo-hua
authors.initials: GH
authors.lastname: Qiu
authors.forename: Yao
authors.initials: Y
authors.lastname: Lu
authors.forename: Hui
authors.initials: H
authors.lastname: Zhao
authors.forename: Min
authors.initials: M
authors.lastname: Yang
authors.forename: Shu-jing
authors.initials: SJ
authors.lastname: Son
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
authors.forename: Shu-feng
authors.initials: SF
authors.lastname: Zhang
authors.forename: Li-jun
authors.initials: LJ
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Cheng
authors.forename: Dao-zhen
authors.initials: DZ
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006513:Hepatitis B e Antigens / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019562:Viral Load
chemical_list: D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha